Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington, [	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours ner resnonse.	0.5								

							. ,			' '								
Name and Address of Reporting Person*  Yeshwant Krishna				2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [ VERV ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
resnwa	ant Krisn	<u>na</u>			1	2 1 0	111010	<del></del>	<u>vieo, 1110.</u> [				X Directo	or	X	10% Ov	vner	
(Last) (First) (Middle) C/O VERVE THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/09/2022							Officer below)	(give title		Other (s below)	specify	
					1													
500 TECHNOLOGY SQUARE, SUITE 901						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)												Line	,	iled by One	Dono	ortina Doroo	_	
CAMBR	IDGE M	IA	02139											iled by More	•	J		
(City)	(5	state)	(Zip)															
		Tab	le I - Non-	-Deriva	ative	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficial	y Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,			Date	Code (Instr. 5)			ed (A) or tr. 3, 4 and	5. Amou Securitie Benefici Owned F Reporte	s Form		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			(IIISU: 4)	
			Table II - D (e						uired, Dis s, options,				Owned					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				ransa ode (l		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$14.04	06/09/2022			A		15,500		(1)	06/08/2032	Common Stock	15,500	\$0.00	15,500	,	D		

## **Explanation of Responses:**

1. This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.

## Remarks:

/s/ Andrew Ashe, Attorney-in-Fact For Krishna Yeshwant

\*\* Signature of Reporting Person

06/13/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.